Ichor Biologics (New York) Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Ichor Biologics (New York) General Information

Description

Developer of human antibody-based treatments designed for infectious diseases. The company engages in antibody discovery, plasma-derived product development, therapeutic research, antibody characterization, laboratory analysis, manufacturing, and research platform technologies, enabling healthcare organizations to access biological therapeutics, support infectious disease treatment, and advance biomedical research.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ichor Biologics (New York) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 01-Nov-2024 Completed Pre-Clinical Trials
4. Accelerator/Incubator 01-Feb-2020 Completed Pre-Clinical Trials
3. Grant 01-May-2019 Completed Pre-Clinical Trials
2. Grant 01-Mar-2017 $250K Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2016 Completed Pre-Clinical Trials
To view Ichor Biologics (New York)’s complete valuation and funding history, request access »

Ichor Biologics (New York) Patents

Ichor Biologics (New York) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12054536-B2 Antibodies to andes hantavirus, and methods for using same Active 22-Mar-2017
US-20200087381-A1 Antibodies to andes hantavirus, and methods for using same Active 22-Mar-2017
US-20220298229-A1 Antibodies to andes hantavirus, and methods for using same Active 22-Mar-2017
US-20240368255-A1 Antibodies to andes hantavirus, and methods for using same Pending 22-Mar-2017
WO-2018175531-A2 Antibodies to andes hantavirus, and methods for using same Inactive 22-Mar-2017 C07K16/10
To view Ichor Biologics (New York)’s complete patent history, request access »

Ichor Biologics (New York) Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Harlem Biospace Accelerator/Incubator
National Institutes of Health Government
FONDEF Government
Entrepreneurship Lab Bio & Health Tech NYC Accelerator/Incubator
To view Ichor Biologics (New York)’s complete investors history, request access »

Ichor Biologics (New York) FAQs

  • When was Ichor Biologics (New York) founded?

    Ichor Biologics (New York) was founded in 2013.

  • Where is Ichor Biologics (New York) headquartered?

    Ichor Biologics (New York) is headquartered in New York, NY.

  • What industry is Ichor Biologics (New York) in?

    Ichor Biologics (New York)’s primary industry is Drug Discovery.

  • Is Ichor Biologics (New York) a private or public company?

    Ichor Biologics (New York) is a Private company.

  • What is Ichor Biologics (New York)’s current revenue?

    The current revenue for Ichor Biologics (New York) is .

  • Who are Ichor Biologics (New York)’s investors?

    Harlem Biospace, National Institutes of Health, FONDEF, and Entrepreneurship Lab Bio & Health Tech NYC have invested in Ichor Biologics (New York).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process